Here are five quick key notes:
1. The five analysts gave the company an average broker rating score of 1.00 — a “strong buy.”
2. The 12-month consensus target price was set at $26.33.
3. The analysts expect the company to post $0.23 earnings per share for the current quarter.
4. K2M traded down 0.36 percent on Tuesday, hitting $24.85.
5. The market cap is $985.43 million.
Northland Securities also recently initiated coverage on the company, setting the price target at $31 and rating the company as “outperform.”
More articles on orthopedic devices:
6 key trends in the North American joint reconstruction market
Orchid opens new India plant—5 things to know
8 trends in the China orthopedic instrument market
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
